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eorg Nickenig, MD,§ Nicholas Curzen, MD, Dominic J. Allocco, MD,¶
eith D. Dawkins, MD¶
iegburg, Hamburg, Trier, and Bonn, Germany; Southampton, United Kingdom;
nd Natick, Massachusetts
bjectives The JACTAX HD trial (“JACTAX” Trial Drug Eluting Stent Trial) evaluated the safety and
linical performance of a novel JACTAX HD (Boston Scientiﬁc Corporation, Natick, Massachusetts)
aclitaxel-eluting stent (PES) in de novo coronary lesions.
ackground The JACTAX HD (Boston Scientiﬁc) stent consists of a pre-crimped bare-metal Liberté
Boston Scientiﬁc) stent coated on its abluminal aspect with an ultrathin (1 m) 1/1 mixture of
iodegradable polylactide polymer and paclitaxel applied as discrete microdots (nominal totals of
.2 g each of polymer and paclitaxel per 16-mm stent).
ethods In this prospective, single-arm, multicenter, ﬁrst-human-use study (n  103), the primary
nd point of 9-month major adverse cardiac events (MACE) (cardiac death, myocardial infarction,
schemia-related target vessel revascularization) was compared with an objective performance crite-
ion (OPC) of 17% (11% MACE based on TAXUS ATLAS [TAXUS Liberté-SR Stent for the Treatment of
e Novo Coronary Artery Lesions] trial results plus a pre-speciﬁed noninferiority margin of 6%).
esults The composite primary end point occurred in 7.8% of JACTAX HD patients with an upper
-sided 95% conﬁdence limit of 13.6%, thus meeting the pre-speciﬁed criteria for noninferiority.
here was no death, Q-wave myocardial infarction, or stent thrombosis through 9 months. In-stent
ate loss was 0.33  0.45 mm, with an in-stent binary restenosis of 5.2% and net volume obstruc-
ion by intravascular ultrasound of 11.4  11.2%.
onclusions The JACTAX HD stent with an abluminal biodegradable polymer showed 9-month
ACE, in-stent late loss, restenosis, and net volume obstruction comparable to that observed with
he TAXUS Liberté (Boston Scientiﬁc) stent coated with a conformal durable polymer. Further studies
re underway to better evaluate the potential of this new PES design, which might allow for more
apid endothelialization and improved vessel healing. (“JACTAX” Trial Drug Eluting Stent Trial;
CT00754728) (J Am Coll Cardiol Intv 2010;3:431–8) © 2010 by the American College of
ardiology Foundation
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Krankenhaus der Barmherzigen Brüder, Trier, Germany; §Medizinische Klinik und Poliklinik II Universitätsklinikum Bonn,
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432rug-eluting stents (DES) that facilitate controlled local
elease of antiproliferative drugs from a durable polymer
elivery system have been shown to significantly reduce
ngiographic restenosis compared with bare-metal stents
BMS) (1–4). The associated reduction in subsequent
epeat revascularization confers no significant difference in
eath or myocardial infarction (MI) (5), but some data
uggest that DES such as the sirolimus-eluting (SES)
YPHER (Cordis Corporation, Miami Lakes, Florida)
tent and the paclitaxel-eluting (PES) TAXUS (Boston
cientific Corporation, Natick, Massachusetts) stent might
increase the risk of late stent
thrombosis (LST) (5,6) due to
delayed arterial healing with in-
complete re-endothelialization
and/or a chronic inflammatory
response (7–9). Several major
medical societies (including the
American Heart Association,
American College of Cardiol-
ogy, and Society for Cardiac
Angiography and Interventions)
now recommend that dual anti-
platelet therapy (DAPT) (thieno-
pyridine and aspirin) be taken for
at least 1 year after DES implan-
tation, if tolerated, to protect
against possible stent thrombosis
(ST) (10,11). The DAPT study
is evaluating whether longer (30
months vs. 12 months) DAPT
might be required (12).
To maintain the antiprolifera-
tive effect of conventional DES
while allowing timelier and more
complete re-endothelialization
(and hopefully minimize LST risk
and the required duration of
DAPT), several manufacturers are
testing DES with abluminally ap-
plied biodegradable polymers
that leave a polymer-free BMS
after drug release is complete.
linical results have been variable. In the randomized
rst-human-use (FHU) FUTURE I (First Use To Under-
core restenosis Reduction with Everolimus) trial, an
verolimus-eluting stent with a continuous abluminal coat-
ng of the bioabsorbable polymer polylactic acid demon-
trated significantly less 6-month in-stent late loss than its
MS control, with comparable 12-month clinical outcomes
13). Similarly, in the randomized FHU STEALTH (Stent
luting A9 BioLimus Trial in Humans) trial, a polylactic
cid biolimus-eluting stent showed significant efficacy in
bbreviations
nd Acronyms
MS  bare-metal stent(s)
I  confidence interval
APT  dual antiplatelet
herapy
ES  drug-eluting stent(s)
S  diameter stenosis
HU  first-human-use
VUS  intravascular
ltrasound
ST  late stent thrombosis
ACE  major adverse
ardiac events
I  myocardial infarction
CT  optical coherence
omography
PC  objective
erformance criterion
ES  paclitaxel-eluting
tent(s)
CA  quantitative coronary
ngiography
ES  sirolimus-eluting
tent(s)
T  stent thrombosis
LR  target lesion
evascularization
VR  target vessel
evascularizationeducing 6-month late loss and percent diameter stenosis tDS) with clinical safety equivalent to the control BMS
14). The subsequent randomized LEADERS (Limus
luted from a Durable versus Erodable Stent Coating) trial
urther showed this stent design was angiographically and
linically noninferior to the CYPHER stent (15). The use
f discrete reservoirs located within the stent strut and filled
ith a drug-polymer mixture has also been tested. In the
onrandomized, open-label PISCES (Paclitaxel In-Stent
ontrolled Elution Study), paclitaxel released from a poly–
actic-co-glycolic acid polymer showed good inhibition of
eointimal hyperplasia in long-duration abluminal release
16); similar results were seen in the EuroSTAR (European
obalt Stent with Antiproliferative for Restenosis) registry
17). In the subsequent large, randomized, controlled
OSTAR (Cobalt Chromium Stent With Antiproliferative
or Restenosis) II study, however, this stent was found to be
nferior to TAXUS (18).
The JACTAX HD stent represents a novel way to
ccomplish abluminal coating, with neither continuous
olymer nor filled wells penetrating stent struts. Instead, a
re-crimped bare-metal Liberté (Boston Scientific Corpo-
ation) stent is abluminally coated with a minimal amount
f biodegradable polylactide polymer plus paclitaxel (nom-
nally 9.2 g of each per 16-mm stent) applied to the
bluminal surface as 2,750 discrete microdots/16-mm stent
Fig. 1). The coating drops impact the stent at high velocity,
llowing the low viscosity solution to spread in a thin layer
nd adhere to the stent surface. At 1 m, the polymer
hickness provided by this approach is approximately 15-
old thinner than that of TAXUS Liberté (Boston Scientific
orporation). The biodegradable polymer is designed to
ully release drug in 60 days and resorb in 4 months, thereby
liminating chronic exposure to drug and polymer. The
oncept of the JACTAX HD (Boston Scientific) stent is
hus to emulate a DES initially and then transition to a
MS. The JACTAX HD trial (“JACTAX” Trial Drug
luting Stent Trial) evaluated safety and clinical perfor-
ance of the JACTAX HD stent in de novo coronary
esions. We report here the 9-month outcomes.
ethods
evice description. The JACTAX HD stent is illustrated in
igure 1. The coating is exclusively abluminal with minimal
mounts of paclitaxel in a low molecular weight biodegrad-
ble polylactide polymer; 3 sides of the stent strut remain
evoid of drug or polymer. Drug is 100% available (no
esidual), and the polymer is designed to resorb completely
n 4 months. Application of the polymer-drug combination
n a pre-mounted stent avoids injury or distortion of the
oating during the crimping process.
tudy design. The prospective, single-arm, multicenter
HU JACTAX HD study (see registry information afterhe abstract) was designed to test whether outcomes in de
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433ovo coronary lesions treated with the JACTAX HD stent
ould be noninferior to an objective performance criterion
OPC) based on outcomes with TAXUS Liberté from the
AXUS ATLAS (TAXUS Liberté-SR Stent for the Treat-
ent of de Novo Coronary Artery Lesions) trial (19). The
rimary end point was 9-month major adverse cardiac
vents (MACE) (defined as cardiac death, MI, and
schemia-driven target vessel revascularization [TVR]) (On-
ine Appendix). Noninferiority was assessed by comparing
he upper 95% confidence interval (CI) of the observed end
oint with an OPC of 17%. The OPC was based on
AXUS ATLAS results (11%) plus a pre-specified nonin-
eriority margin of 6%, chosen to ensure that the JACTAX
D stent would have similar clinical performance to that of
AXUS Liberté.
atient selection, procedure, and follow-up. Eligible pa-
ients (18 years) had a de novo lesion in a native coronary
rtery and clinical and angiographic indications for percu-
aneous coronary intervention. Key angiographic inclusion
riteria were lesion length 20 mm, stenosis 70%, and
eference vessel diameter of 2.75 to 3.5 mm (visual esti-
ate). One nontarget lesion, located in a different vessel
istribution, could also be treated. The nontarget lesion was
o be successfully treated first with either a TAXUS Liberté
ES or a BMS. Key exclusion criteria included excessive
arget lesion tortuosity; involvement of a side branch 2.0
m in diameter; moderate or severe calcification of the
arget lesion; MI 72 h before the procedure; stroke or
ransient ischemic attack 3 months before the procedure;
nd allergy or contraindication to aspirin, clopidogrel, or
tainless steel. Study enrollment occurred after successful
re-dilation of the study vessel and introduction of the
Figure 1. JACTAX HD Stent
The JACTAX HD drug-eluting stent is a Liberté stent coated with the Juxtapos
ular weight biodegradable carrier polymer polylactide (1/1 by weight; nominal
stent in discrete areas (approximately 3.4 ng polymer/microdot; see box). Thre
(97 m) and polymer (1 m) together are 98 m thick.ACTAX HD stent. sPatients received DAPT (150 mg aspirin plus 300 mg
lopidogrel) before or immediately after the procedure.
spirin (150 mg daily) was mandated by the protocol for 12
onths and recommended indefinitely. Thienopyridine (75
g clopidogrel daily) was mandated for 6 months and
ecommended for 12 months per local practice. Clinical
ollow-up was scheduled at 1 month and 4, 9, 12, and 24
onths. Follow-up quantitative coronary angiography
QCA) and intravascular ultrasound (IVUS) were scheduled
t 9 months.
Ethics review committees of participating institutions
pproved the protocol. Patients provided written informed
onsent before enrollment. The study was conducted under
ood Clinical Practice conditions and in compliance with
he medical device regulations for the participating coun-
ries (Germany and the United Kingdom). The Online
ppendix lists the sponsor, core laboratories, and contract
esearch organization managing the study.
nd points and data management. The primary end point
as 9-month MACE. Secondary end points included ST
efined per the Academic Research Consortium definitions
20) and assessments of restenosis based on core laboratory
nalyses of QCA and IVUS results. Monitors independent
f the sponsor verified all data from case report forms. An
ndependent medical monitor adjudicated MACE and ST,
nd an autonomous data monitoring committee periodically
eviewed safety data (Online Appendix).
Angiographic late loss and binary restenosis results were
ompared with results for a cohort of selected patients from
he TAXUS ATLAS study (19). The 2 studies had similar
nclusion/exclusion criteria; the main differences were
esion-based. Thus the TAXUS ATLAS comparator con-
rathin Abluminal Coating process, which applies paclitaxel in the low molec-
g of each per 16-mm stent) onto the abluminal surface of a pre-mounted
s of each stent strut remain bare, covered by neither polymer nor drug. Struted Ult
ly 9.2
e sideisted of patients who would have met the slightly more
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434estrictive JACTAX HD lesion criteria (site reported lesion
ength 20 mm, percent DS 70 mm, and reference vessel
iameter of 2.75 to 3.5 mm).
tatistical methods. The analysis sample for the primary
nd point was the intent-to-treat population. Patient, le-
ion, and procedural characteristics and event rates were
nalyzed with descriptive statistics with SAS version 9.1 or
igher (SAS Institute, Inc., Cary, North Carolina). Simple
roportions with 95% CIs were used for categorical vari-
bles; continuous data are provided as mean  SD and/or
edian with interquartile range.
The statistical objective of the trial was to achieve a
recision of 6% on the estimate for the 9-month composite
ACE rate with a 1-sided 95% CI. The MACE rate was
stimated to be 11.0% on the basis of results obtained with
he TAXUS Liberté stent in the TAXUS ATLAS trial
19). A sample size of 100 patients was determined neces-
ary, with exact calculations based on the binomial distri-
ution (21), to produce a 95% CI (PASS 2005 Power and
ample Size Software, NCSS Statistical Software, Kaysville,
tah). Thus, noninferiority of JACTAX HD to TAXUS
iberté was determined by comparing the 1-sided 95%
pper confidence bound of the observed 9-month MACE
ate (calculated by the Clopper-Pearson exact method) with
n OPC of 17% (11% plus the pre-specified margin of 6%).
Table 1. Baseline Demographic Data and Target Lesion Characteristics
JACTAX HD
(n  103)
Patient characteristics
Men 80.6 (83)
Age (yrs) 65.6 8.9
Smoking 46.6 (48)
Stable angina 67.9 (70)
Unstable angina 19.4 (20)
Diabetes mellitus 21.4 (22)
Insulin 6.8 (7)
Hyperlipidemia 71.8 (74)
Hypertension 80.6 (83)
Previous PCI 42.7 (44)
Previous CABG 12.6 (13)
Target lesion characteristics*
Target lesion RVD, mm 2.8 0.4
Lesion length, mm 13.7 5.8
Percent diameter stenosis, % 72.4 10.9
Location
Left anterior descending artery 40.8 (42)
Circumﬂex/obtuse marginal 31.1 (32)
Right coronary artery 28.2 (29)
Values are % (n) or mean  SD; data shown are for the intent-to-treat population.
*Core laboratory analysis.
CABG  coronary artery bypass graft; PCI  percutaneous coronary intervention; RVD 
reference vessel diameter.tatistical significance was determined with the exact-sided p value of the binomial test for the study hypothesis;
 0.05 was considered significant.
esults
atient, lesion, and procedural characteristics. The JACTAX
D study enrolled 103 patients at 5 sites in Germany and
ngland (Online Appendix). Baseline demographic data
nd target lesion characteristics are shown in Table 1. There
ere 127 lesions treated, including 24 nonstudy lesions; 110
evices were implanted to treat 103 target lesions in 103
atients. Device technical success, defined as successful
elivery and stent deployment, was 99.1% (109 of 110, 1
eographical miss). Lesion success, defined as successful stent
elivery and deployment to the intended lesion location with
hrombolysis In Myocardial Infarction flow grade 2 to 3 and
S 30% by QCA, was 99.0% (102 of 103, 1 patient with
0.7% DS). Procedural success (lesion success with no MACE
hrough discharge) was 97.1% (100 of 103, 1 case with lesion
ailure and 2 patients with non–Q-wave MI).
linical outcomes at 30 days and 9 months. Clinical out-
omes are shown in Table 2. The composite primary end
oint occurred in 7.8% of patients and consisted of 2
on–Q-wave MIs and 6 ischemia-driven TVRs, of which 2
ere target lesion revascularizations (TLRs). The upper
-sided 95% CI of the primary end point, calculated by the
lopper-Pearson exact method, was 13.6%. This value was
elow the control comparator of 17% (OPC based on the
AXUS ATLAS trial result of 11% plus the pre-specified
argin of 6%), thereby indicating noninferiority of the
ACTAX HD to TAXUS Liberté stent (p  0.006 for
oninferiority). The total TVR rate (including ischemia-
riven and non–ischemia-driven events) was 10.7% (n 
1), of which 4.9% (n 5) were adjudicated as TLR. There
as no death, Q-wave MI, or ST through 9 months.
Table 2. Clinical Outcomes at 30 Days and 9 Months
30 Days
(n  103)
9 Months
(n  103)
All death 0.0 (0) 0.0 (0)
Major adverse cardiac events* 1.9 (2) 7.8 (8)
Cardiac death 0.0 (0) 0.0 (0)
Myocardial infarction 1.9 (2) 1.9 (2)
Q-wave 0.0 (0) 0.0 (0)
Non–Q-wave 1.9 (2) 1.9 (2)
TVR, ischemia driven 0.0 (0) 5.8 (6)
TLR 0.0 (0) 1.9 (2)
Nontarget lesion TVR 0.0 (0) 3.9 (4)
Stent thrombosis† 0.0 (0) 0.0 (0)
Values are % (n); data are binary rates. *Includes cardiac death, myocardial infarction, and
ischemia-driven target vessel revascularization (TVR). †Definite plus probable per Academic
Research Consortium definitions (20).TLR target lesion revascularization.
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435CA and IVUS results. Table 3 shows results of QCA (n 
7) and 3-dimensional IVUS (n  62) paired lesion
nalyses. At 9 months, in-stent binary restenosis was 5.2%
nd in-stent late loss was 0.33  0.45 mm. The cumulative
requency distribution of angiographic in-stent late loss for
ACTAX HD was comparable to that observed in similar
atched patients selected from the TAXUS ATLAS trial
19) (Fig. 2). The data distribution was somewhat skewed in
oth groups, and Figure 3 shows the median and interquartile
ange for in-stent and in-segment late loss. Binary restenosis
as also similar for the 2 groups (Fig. 4). Two patients (3.2%)
ad incomplete stent apposition immediately after stent place-
ent and at 9-month follow-up; no cases of late incomplete
pposition were observed. Mean net volume obstruction by
VUS was 11.4 11.2%; the median was 8.5% with 25th and
5th percentiles of 1.3% and 18.4%, respectively.
iscussion
his FHU study evaluated safety and clinical performance
f the novel JACTAX HD stent, which consisted of a
re-crimped bare-metal Liberté stent with an abluminal
oating of paclitaxel in an ultrathin biodegradable polymer
pplied as a controlled pattern of microdots. The JACTAX
oat weight (20 g) is 10% of that of other abluminal
tents with biodegradable polymers in current clinical test-
Table 3. JACTAX HD Quantitative Coronary Angiography and 3D IVUS
Paired Lesion Analyses
Quantitative Coronary Angiography
Parameter
Pre-Procedure
(n  97)
Post-Procedure
(n  97)
9 Months
(n  97)
RVD 2.78 0.43 2.80 0.42 2.75 0.44
MLD (in stent), mm — 2.60 0.37 2.27 0.57
MLD (in segment), mm 0.78 0.35 2.19 0.45 2.05 0.54
Percent DS (in stent) — 6.73 9.09 17.66 15.84
Percent DS (in segment) 72.32 11.01 21.91 9.60 25.86 13.57
Late loss (in stent) — — 0.33 0.45
Late loss (in segment) — — 0.14 0.39
Binary restenosis (in stent) — — 5.15%
Binary restenosis (in segment) — — 6.19%
3D IVUS
Parameter
Index Procedure
(n  62)
9 Months
(n  62)
Stent volume, mm3 149.1 52.5 157.7 64.0
Lumen volume, mm3 149.1 52.6 140.9 60.5
Malapposition 3.2 (2) 3.2 (2)
Neointimal volume, mm3 — 17.6 18.3
Net volume obstruction, % — 11.4 11.2
Data are mean SD, %, or % (n).
DS  diameter stenosis; IVUS  intravascular ultrasound; MLD  minimal lumen diameter;RVD reference vessel diameter; 3D 3-dimensional.ng. Safety and efficacy of the JACTAX HD stent compared
ell with an OPC based on TAXUS ATLAS patients
reated with TAXUS Liberté (19). The observed 9-month
omposite MACE rate of 7.8% had a 1-sided upper 95%
onfidence bound of 13.6%, which was significantly (p 
.006) below the 17% noninferiority boundary. This dem-
nstrates noninferiority (equivalence or better) of the
ACTAX HD stent to the TAXUS Liberté stent in this
omposite of safety and efficacy events, with no episodes of
eath, Q-wave MI, or ST through 9 months.
Similarly, late loss with JACTAX HD (0.33  0.45 mm
n-stent; 0.14  0.39 mm in-segment) was comparable to
r better than that observed with TAXUS EXPRESS
r TAXUS Liberté in numerous prior clinical trials
2,18,19,22–24). This measure of efficacy was also con-
Figure 2. Cumulative Frequency Distribution of In-Stent Late Loss:
JACTAX HD and TAXUS ATLAS Patients at 9 Months
The TAXUS ATLAS patient cohort is described in the Methods section.
Figure 3. Late Loss in JACTAX HD and TAXUS ATLAS Patients at
9 Months
The ﬁgure shows the median and interquartile range and the skewed data
distribution in both groups.
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436rmed by the low neointimal hyperplasia volume percentage
f 11.4  11.2% by IVUS and by the low rate of clinical
LR (1.9% at 9 months).
These results show that an ultrathin abluminal biode-
radable approach can match the performance of a conven-
ional TAXUS stent with a thicker conformal permanent
olymer coating and significantly higher drug dose. Release
f sirolimus from a polymer reservoir was recently shown to
e superior to TAXUS in the NEVO RES-ELUTION I
A Randomized, Multi-Center, Single-Blind Comparison
f the Conor Cobalt Chromium Reservoir Based Stent
ith Sirolimus Elution Versus the TAXUS Liberté
aclitaxel-eluting Coronary Stent System in De Novo
ative Coronary Artery Lesions) trial with a primary end
oint of 6-month late loss (25). This contrasts with clinical
utcomes in the COSTAR II trial where reservoir-based
bluminal release of paclitaxel was shown to be inferior to
AXUS (18).
The use of polymer-free DES platforms has also been
nvestigated clinically, with mixed results. The randomized
LUTES (European evaLUation of pacliTaxel Eluting
tent), ASPECT (Asian Paclitaxel-Eluting Stent Clinical
rial), and DELIVER trials compared BMS with abluminally
oated, polymer-free paclitaxel stents. In the ELUTES trial,
he highest-dose PES showed significantly less 6-month
ate loss with comparable 12-month clinical results (26). In
he ASPECT trial, the highest-dose PES showed signifi-
antly less 6-month in-stent neointimal hyperplasia, but
hat advantage was lost to late “catch-up” by 2 years (27).
mong DELIVER patients with angiographic follow-up,
-month in-stent late loss was significantly less, but there
as no significant difference in the primary end point of
Figure 4. Binary Restenosis in JACTAX HD and TAXUS ATLAS Patients
at 9 Months
The ﬁgure shows comparable results for binary restenosis between the
JACTAX HD group and a matched patient cohort selected from the TAXUS
ATLAS trial (described in the Methods section).arget vessel failure or the secondary end point of binary restenosis (28). The polymer-free sirolimus-eluting ISAR
tent showed similar late loss versus TAXUS in the ran-
omized ISAR-TEST (Rapamycin-Eluting Stents With
ifferent Polymer Coating to Reduce Restenosis) trial (29)
ut failed to show noninferiority when compared with the
YPHER stent (30). More recently, in the randomized
SAR-TEST-2 trial, a dual-DES with sirolimus and the
ntirestenotic agent probucol showed significantly less late
oss at 6 to 8 months versus the polymer-based zotarolimus-
luting stent but was comparable to the CYPHER stent (31).
Although the JACTAX HD late loss efficacy data are
omparable to that of the TAXUS stent, there is no direct
roof in this study that this approach provides more rapid,
omplete, or functional endothelial coverage to potentially
educe the risk of very late ST (1 year) (6–9,32,33) or
horten the duration of required DAPT. Optical coherence
omography (OCT) imaging can provide some assessment
f endothelial coverage. In 34 SES patients (57 stents),
atsumoto et al. (34) found that at 6 months only 16%
howed complete stent strut coverage. Takano et al. (35)
eported that, at 3-month follow-up, 95% (20 of 21) of SES
atients had some exposed struts (n  31 SES). On a
er-strut basis, the rate of exposed struts was 15%, of which
% were exposed with malapposition. These rates were
ignificantly higher in acute coronary syndrome lesions (35).
he 15% frequency of exposed struts at 3 months decreased
o 5% at 2 years, but the difference was not statistically
ignificant (36). In a randomized trial comparing SES with
nd without polymer (n  12/group), mean neointimal
hickness at 90 days was significantly less for the polymer-
oated stent, but more struts were uncovered (10% vs.
3%, respectively) (37). Previous studies have suggested
hat 30% uncovered struts/cross-section might correlate
ith the occurrence of LST (8).
Studies are underway to better evaluate the potential for
ore rapid endothelialization and improved vessel healing
ith the JACTAX HD stent, but a preliminary ad hoc OCT
nalysis (20 m resolution) of 13 patients at 1 center in this
tudy found most examined struts covered at 9 months (38).
urther OCT assessment of vascular response to the JACTAX
D stent is ongoing in the Optical Coherence Tomography
rug Eluting Stent Investigation (NCT00776204), which will
valuate the extent of strut coverage and malapposition with
ACTAX versus TAXUS Liberté in de novo coronary lesions
t 6 months in 60 patients with high-resolution (approximately
0 to 15 m axial) OCT. Larger clinical studies with long-
erm follow-up, however, will be necessary to determine
hether use of the JACTAX HD stent results in reduced very
ate ST rates, providing a potential opportunity to reduce the
eed for DAPT.
tudy limitations. Limitations of this study include the
mall number of patients with relatively simple lesions,
ypical of an FHU study, together with the absence of a
andomized control group.
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437onclusions
he results of the JACTAX HD trial show that the novel
ACTAX HD stent with an ultrathin abluminal coating of
iscrete microdots of paclitaxel mixed with drug delivery
ontrolled by a biodegradable polymer can provide safety
nd effectiveness end points comparable to those achieved
ith the conventional conformal durable polymer TAXUS
iberté stent. Further studies are underway to more rigor-
usly evaluate this potential for the JACTAX design to
llow more rapid endothelialization and potentially reduce
he requirement for prolonged DAPT.
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APPENDIX
or additional definitions and lists of study participants, please see the
nline version of this article.
